Table 2.

Enrolled patients and ATLAS results

PatientsAgeSexEthnicityTumorPrior therapyTMB (mutations/Mb)NeoantigensInhibigensPeptides in vaccine
A53FWhiteSquamous NSCLCSurgery/Carbo/Etop0.186010a
B73MWhiteUrothelial carcinomaSurgery/Mito Cis/Gem/Pembro0.91648
C82MWhiteMelanomaSurgery/Pembro/Ipi8.161994116
D48MWhiteMelanomaSurgery3.094394Recurrence prior to vaccination
E64MWhiteUrothelial carcinomaSurgery/Cis/Gem0.8818113
F66FWhiteNSCLC adenocarcinomaSurgery0.9416911
G57MWhiteBladderSurgery2.342410413
H64FWhiteUrothelial carcinomaSurgery/Cis/Gem0.441448
I68FWhiteUrothelial carcinomaSurgery/Gem0.1203No stimulatory antigens
J68MWhiteBladderSurgeryInsufficient tumor
K68MWhiteSCCHNCetux/XRT3.1915159
L76MWhiteSCCHNCarbo/Taxol/XRT0.521Insufficient antigens
  • Abbreviations: SCCHN, squamous cell carcinoma of the head and neck; Carbo, carboplatin; Cetux, cetuximab, Cis, cisplatin; Etop, etoposide; Gem, gemcitabine; ipi, ipilimumab; Mito, mitomycin-C; pembro, pembrolizumab; XRT, radiotherapy.

  • aTwo peptides each for four deletion fragments positive in ATLAS.